Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma

Lenvatinib was recently approved as a novel first-line molecular targeted agent (MTA) for treating hepatocellular carcinoma (HCC). The importance of relative dose intensity (RDI) has been shown in the treatment of various types of cancers. However, RDI may not accurately reflect the treatment intens...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancers (Basel)
Huvudupphovsmän: Eso, Yuji, Nakano, Shigeharu, Mishima, Masako, Arasawa, Soichi, Iguchi, Eriko, Nakamura, Fumiyasu, Takeda, Haruhiko, Takai, Atsushi, Takahashi, Ken, Taura, Kojiro, Seno, Hiroshi
Materialtyp: Artigo
Språk:Inglês
Publicerad: MDPI 2019
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7016578/
https://ncbi.nlm.nih.gov/pubmed/31877859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12010049
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk